Eli Lilly and Company $LLY Shares Sold by Hartline Investment Corp

Key Points

• Hartline Investment Corp cut its Eli Lilly stake by 20.2% in the fourth quarter, selling 3,485 shares and leaving it with 13,760 shares worth about $14.8 million.
• Wall Street sentiment remains broadly positive: analysts including Goldman Sachs and Jefferies raised price targets to $1,283 and $1,330, respectively, while the stock’s consensus rating is still Moderate Buy.
• Eli Lilly continues to post strong fundamentals, reporting $8.55 EPS and $19.8 billion in quarterly revenue, both above expectations, as revenue jumped 55.5% year over year and the company maintained its dividend payout.

Hartline Investment Corp trimmed its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 20.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 13,760 shares of the company's stock after selling 3,485 shares during the period. Eli Lilly and Company comprises about 1.6% of Hartline Investment Corp's portfolio, making the stock its 15th largest holding. Hartline Investment Corp's holdings in Eli Lilly and Company were worth $14,788,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of LLY. Cidel Asset Management Inc. boosted its holdings in shares of Eli Lilly and Company by 26.5% during the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock worth $20,392,000 after purchasing an additional 5,591 shares during the last quarter. Spire Wealth Management boosted its holdings in shares of Eli Lilly and Company by 2.2% during the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company's stock worth $29,789,000 after purchasing an additional 592 shares during the last quarter. Coldstream Capital Management Inc. boosted its holdings in shares of Eli Lilly and Company by 25.6% during the 3rd quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company's stock worth $32,365,000 after purchasing an additional 8,659 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 30.8% during the 4th quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company's stock worth $33,471,000 after purchasing an additional 7,338 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky boosted its holdings in shares of Eli Lilly and Company by 3.5% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company's stock worth $126,022,000 after purchasing an additional 5,595 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently commented on LLY. Freedom Capital raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, February 10th. Morgan Stanley reaffirmed an "overweight" rating and set a $1,344.00 price target on shares of Eli Lilly and Company in a research report on Friday, May 1st. CICC Research lifted their price target on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a "neutral" rating in a research report on Wednesday, February 11th. Argus lifted their price target on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a "buy" rating in a research report on Monday, February 9th. Finally, Loop Capital set a $1,200.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $1,220.37.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs reaffirmed its Buy rating on LLY and raised its price target to $1,283, signaling confidence in further upside. MarketScreener Latest Ratings
• Positive Sentiment: Jefferies lifted its price target on Eli Lilly to $1,330, also implying meaningful upside from recent trading levels. MarketScreener
• Positive Sentiment: New clinical updates across Lilly’s pipeline, including positive obesity conference data, Alzheimer’s study progress, and a new heart-failure trial, help reinforce the market’s view that Lilly has multiple growth drivers beyond its current diabetes and obesity drugs.
• Neutral Sentiment: Lilly also announced an acquisition of Engage Biologics, extending its gene-therapy ambitions; this supports long-term diversification, but the near-term stock impact is less direct. Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,066.59 on Friday. The company has a fifty day simple moving average of $942.87 and a two-hundred day simple moving average of $1,003.77. The company has a market cap of $1.00 trillion, a price-to-earnings ratio of 37.89, a price-to-earnings-growth ratio of 1.16 and a beta of 0.48. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company's quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company's payout ratio is 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.